Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase NA × Liver Neoplasms × tislelizumab × Clear all

Phase

Phase 2 2 Phase NA 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 3 Adenocarcinoma of Lung 2 Recurrence 1 Non-Small Cell Lung Cancer Without Mutation in Epidermal Growth Factor Receptor (Disorder) 1 Neoplasms 1 Liver Neoplasms 1 Glioblastoma 1 Endometrial Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Advanced Solid Tumor 1

Interventions

Radiofrequency Ablation 5 lenvatinib 4 Radiosurgery 4 Electroporation 4 Radiotherapy 3 Hepatectomy 3 sintilimab 2 perflutren 2 Proton Therapy 2 Patient Navigation 2 Nutritional Status 2 Magnetic Resonance Spectroscopy 2 Liver Transplantation 2 Injections 2 Exercise 2 Dextrins 2 Cryosurgery 2 Control Groups 2 Anesthesia, General 2 toripalimab 1 tislelizumab 1 seocalcitol 1 pembrolizumab 1 motexafin gadolinium 1 gadofosveset trisodium 1 gadobutrol 1 gadobenic acid 1 erythromycin propionate-N-acetylcysteinate 1 durvalumab 1 camrelizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05339581 2022-04-27

iPLENTY-pvtt

RenJi Hospital

Phase NA Unknown

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡